Six of eight evaluable patients
Six of eight evaluable patients with urothelial carcinoma had partial responses to TJ101, or 75%, Phrontline Biopharma said. The group included patients who had previously been treated with enfortumab vedotin and pembrolizumab, the company said. The preliminary results were presented at the European Society for Medical Oncology Congress 2026 in Madrid on 23 October.
Other tumour types and a Phase Ib start
The company said preliminary antitumor activity was also seen in squamous non-small cell lung cancer, small cell lung cancer and prostate cancer, which it said supported further clinical investigation in those indications. It also announced the initiation of a Phase Ib study, with the first patient dosed.
Dosing and safety review
Dose escalation is continuing and alternative treatment schedules are being explored to optimise the therapy's potential, the company said. Martín Sebastian Olivo, chief medical officer, said the responses in patients previously treated with enfortumab vedotin and pembrolizumab were especially promising, and that dosing and schedules were still being optimised.
What TJ101 is
Phrontline Biopharma is a clinical-stage biotechnology company headquartered in Hangzhou, China. TJ101 is an investigational bispecific antibody-drug conjugate targeting EGFR and B7-H3 that incorporates a topoisomerase I inhibitor payload, and it is being evaluated in a global Phase I study in patients with advanced solid tumours. It has not been approved by any regulatory authority, and its safety and efficacy have not been established.
